CAPTRUST Financial Advisors
MCRB icon

CAPTRUST Financial Advisors’s Seres Therapeutics MCRB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-655
Closed -$9.17K – 2561
2025
Q1 		$9.17K Hold
655
– – ﹤0.01% 2340
2024
Q4 		$10.9K Hold
655
– – ﹤0.01% 2279
2024
Q3 		$12.4K Buy
+655
New +$13.3K ﹤0.01% 2267
2022
Q2 		– Sell
-5
Closed -$1K – 5056
2022
Q1 		$1K Sell
5
-11
-69% -$1.69K ﹤0.01% 4712
2021
Q4 		$3K Buy
16
+5
+45% +$794 ﹤0.01% 4286
2021
Q3 		$2K Sell
11
-15
-58% -$2.94K ﹤0.01% 4275
2021
Q2 		$12K Buy
26
+18
+225% +$7.59K ﹤0.01% 3447
2021
Q1 		$3K Buy
+8
New +$3.68K ﹤0.01% 3921

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

CAPTRUST Financial Advisors's MCRB Position: Q2 2025 in Review

CAPTRUST Financial Advisors sold out of Seres Therapeutics (MCRB) in Q2 2025, closing a stake of 655 shares — an estimated $9.17K sold.

CAPTRUST Financial Advisors first reported a position in MCRB in Q1 2021 and held it in 8 quarters. The position peaked at $12.4K in Q3 2024. 33 funds tracked by Wall St. Rank hold MCRB as of Q2 2025.

  • CAPTRUST Financial Advisors reported no remaining Seres Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 655 Seres Therapeutics shares in Q2 2025, an estimated $9.17K.
  • CAPTRUST Financial Advisors first reported a position in Seres Therapeutics in Q1 2021 and held it in 8 quarters.
  • CAPTRUST Financial Advisors's Seres Therapeutics position peaked at $12.4K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2025.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2025, filed 15 Aug 2025.